Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients with MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age	Shire Human Genetic Therapies, Inc	Ongoing	Elaprase	4	SHPELA401	King Faisal Specialist Hospital and Research Center (Riyadh)
"CLCZ696B2401-TRANSITION (A multicenter, randomized, open label, parallel group studycomparing pre-discharge and posT-discharge tReatmentinitiation with LCZ696 in heArt failure patieNtS withreduced ejectIon-fracTion hospItalized for an acutedecOmpensation eveNt (ADHF)"	Novartis	Ongoing	Entresto (SACUBITRIL, VALSARTAN)	4	CZ696B2401	Saud Al-Babtain Cardiac Center (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah), King Faisal Specialist Hospital and Research Center (Riyadh), King Khalid University Hospital (Riyadh)
"A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition tothe Paliperidone Palmitate 3-Month Formulation in Patients with SchizophreniaPreviously Stabilized on the Paliperidone Palmitate 1-Month Formulation"	Janssen-Cilag International NV	Ongoing	paliperidone	3	R092670SCH3015	Jeddah psychiatric hospital, Al-Amal Complex for mental health (Dammam)
"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial withan open-label extension that investigates the effect of the addition of dulaglutide (0.75 and1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baselinein hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus"	Eli Lilly	Ongoing	Dulaglutide 0.75 /1.5 mg	3	H9X-MC-GBGC	King Khalid University Hospital (Riyadh), International Medical Center (Jeddah)
"A Randomized controlled Trial of Influenza Vaccineto Reduce Adverse Vascular Events"	McMaster University	Ongoing	Vaxigrip	3	version 2	King Khalid University Hospital (Riyadh), King Abdulaziz University Hospital (Jeddah), King Fahad Medical City (Riyadh), Madinah Cardiac Center
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity	Novartis	Ongoing	Ranibizumab	3	CRFB002H2301 V 01	King Faisal Specialist Hospital and Research Center (Riyadh)
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity	Novartis	Ongoing	Ranibizumab	3	CRFB002H2301 V 01	King Faisal Specialist Hospital and Research Center (Riyadh)
Phase 2 study of 5 Days azacytidine priming prior to fludarabine, cytarabine and G-CSF combination for patients with relapsed or refractory AML.	King Fahad Medical City	Ongoing	Vidaza	2	Version 1.1	King Fahad Medical City (Riyadh)
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	Bristol-Myers Squibb	Terminated	NIVOLUMAB/IPILIMUMAb	3	CA209-227	King Faisal Specialist Hospital and Research Center (Riyadh)
Asia and Latin America Fracture Observational Study	Eli Lilly	Ongoing	Forteo (teriparatide)	4	B3D-MC-B02	King Fahad Medical City (Riyadh), Al-Noor Specialist Hospital, King Fahad Hospital (Jeddah), Sabia General Hospital, King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar)